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Chemokines are a family of small cytokines that share a typical key structure that is 
stabilized by disulfide bonds between the cysteine residues at the NH2-terminal of the 
protein, and they are secreted by a great variety of cells in several different conditions. 
Their function is directly dependent on their interactions with their receptors. Chemokines 
are involved in cell maturation and differentiation, infection, autoimmunity, cancer, and, in 
general, in any situation where immune components are involved. However, their role in 
postfracture inflammation and fracture healing is not yet well established. In this article, 
we will discuss the response of chemokines to bone fracture and their potential roles in 
postfracture inflammation and healing based on data from our studies and from other 
previously published studies.
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iNTRODUCTiON
Bone fracture healing is a complex progression of events that require a timely sequence of interactions 
between cells and their mediators. Both resident and infiltrating cells contribute to the three phases 
of fracture healing: inflammation (initial hematoma with subsequent infiltration of inflammatory 
cells), bone formation, and bone remodeling (1, 2).
Approximately 7.9 million fractures occur in the United States every year, and nearly 5–20% 
exhibit delay or disruption in healing, resulting in significant morbidity and reduced productivity 
(3, 4). Thus, understanding the molecular mechanisms involved in postfracture inflammation and 
repair have the obvious potential to improve the quality and the time of fracture healing and translate 
into significant therapeutic benefit in both patient outcomes and reduced costs to society.
Delayed bone fracture healing and non-union fractures represent an important clinical problem, 
especially in patients with open fractures, patients with diabetes, and patients with multiple fractures 
who also suffer from posttraumatic systemic inflammation. However, the underlying biochemical 
and cellular mechanisms that become dysregulated during delayed union and non-union fracture 
repair remain controversial.
A key initial step in fracture repair is an inflammatory reaction involving immune cells that 
become activated immediately in response to tissue damage. Although much is known about the 
function of inflammatory cells as well as the other cells that migrate within the fracture in response 
to injury, little is known about the chemotactic and activation signals that influence this response. 
It is now well accepted that chemokines promote inflammation (5–7) and angiogenesis (8–10). In 
addition, chemokines are thought to play an important role in several aspects of bone metabolism 
including the recruitment of leukocytes and the formation of osteoclasts (11, 12). Therefore, they 
may contribute to the regulation of osteoneogenesis, by integrating inflammatory events and the 
reparative processes important in modulating fracture healing.
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This review will discuss chemokine expression in response 
to bone fracture and the potential role of these molecules in 
postfracture inflammation and healing.
CHeMOKiNeS AND CHeMOKiNe 
ReCePTORS
Chemokines belong to a family of small cytokines. There are 
approximately 50 chemokines (13, 14) interacting with some 23 
different receptors (15–19). They range in size from 8 to 20 kDa 
and share a basic structure that is stabilized by disulfide bonds 
between cysteine residues. Based on the pattern of cysteine 
residues near the N-terminus, chemokines can be divided into 
four subfamilies (20): (1) the CC subfamily, which includes beta 
chemokines, has cysteine residues adjacent to each other; (2) the 
CXC subfamily, which includes alpha chemokines, has cysteine 
residues that are separated by an intervening amino acid; (3) 
the C subfamily has one cysteine residue at the N-terminus of 
the protein; and (4) the CX3C family, with only one representa-
tive, CX3CL1 (also known as neurotactin and fractalkine), in 
which the two cysteine residues are separated by three amino 
acids (21).
Chemokines are secreted by a great variety of cells such as 
mononuclear leukocytes (22–24), neutrophils (25–28), eosino-
phils (29), fibroblasts (30, 31), blood endothelial cells (32), and 
adipocytes (33, 34). They can be induced in several different 
conditions. The name “chemokine” is derived from the ability of 
chemokines to induce directed chemotaxis in nearby responsive 
cells. Some chemokines are considered pro-inflammatory and 
can be induced during an immune response to attract cells of 
the immune system to a site of infection, whereas others are 
considered homeostatic and are involved in controlling the 
migration of cells during normal physiological conditions (35, 
36). Chemokines play roles in cell maturation and differentiation, 
infection, autoimmunity, cancer, and, in general, in any situation 
where immune components are involved. However, their role in 
postfracture inflammation and fracture healing is not yet well 
established.
Chemokine function is directly dependent on the interaction 
with chemokine receptors. Chemokine receptors are G protein-
linked transmembrane receptors located on the surfaces of target 
cells (15, 37). Chemokines bind their cognate G protein-coupled 
receptors and trigger intracellular calcium fluxes. As a concentra-
tion of chemokines increases, calcium flux signaling continue to 
increase till it reaches a plateau, while cell migration increases 
with the increase of chemokine concentration but then returns 
to baseline. Typically, a moderate increase in chemokines’ con-
centration leads to chemotactic migration, but a huge increase in 
the concentration of chemokines could halt cell migration (38). 
However, the signaling mechanisms that govern this phenom-
enon remain unclear.
There are 20 signaling chemokine receptors (37) and three 
non-signaling or scavenger receptors that serve to mediate 
chemokine-dependent signaling by binding, internalizing, 
and degrading chemokines (39, 40). Though similar to other 
seven-transmembrane receptors, signaling chemokine receptors 
share certain structural features, such as the highly conserved 
DRYLAIV amino acid sequence in the second intracellular 
loop (41), a feature that is absent in decoy receptors, indicating 
its implication in signaling. Several studies have shown that 
chemokine receptors are expressed on the surface of cells as both 
homo- and heterodimers (42–45), but the stability of the dimer is 
likely dependent on the presence of the ligand.
In a recent article, Muñoz et al. (46) have described the differ-
ent types of dimerizations that occur between chemokine recep-
tors, with ligands and receptors forming complexes in a dynamic 
equilibrium (47, 48), underscoring the complexity of chemokine 
activities. However, the lack of specific tools for stabilizing het-
erodimeric complexes, combined with the constantly changing 
equilibrium between receptor conformations, has complicated 
the studies of signaling functions of each dimer and limited our 
ability to modulate chemokine/receptor interaction using phar-
macological approaches.
CHANGeS iN THe eXPReSSiON OF 
CHeMOKiNeS iN ReSPONSe TO 
FRACTURe AND THeiR POTeNTiAL ROLe 
iN FRACTURe HeALiNG
Although the function of the various cell types involved in 
postfracture inflammation is well established, the molecular 
mechanisms underlying the different phases of the bone repair 
process are still poorly understood. A thorough elucidation of 
how the spatial and temporal expression of chemokines and their 
receptors are modulated postfracture is ultimately essential to 
our understanding of the role of these chemokines in fracture 
repair.
Neutrophils are one of the most important cell types in the 
postfracture inflammation response. They are the first cell type 
to arrive at the fracture site in response to injury (49). They also 
express and produce chemokines that serve to attract further 
immune cells that ultimately participate in the healing process. 
A recent study, making use of a rat model in which a 5-mm 
bone defect was created in the femur, has reported the detection 
of neutrophils, a few granulocytes, and a few monocytes at the 
site of the defect as early as 12 h postfracture (49). The study 
also found that the number of neutrophils peaked at 24–48 h 
postfracture, marking the beginning of the inflammatory stage 
in this particular model system. Eosinophils and basophile 
granulocytes were seen 24  h postsurgery. In addition, protein 
expression of the major pro-inflammatory cytokine IL-6 and 
three major neutrophil chemoattractants, CXCL1, CXCL2, and 
CXCL3 (49), showed an increase in concentration immediately 
after surgery and a re-equilibration to baseline before 24  h 
postsurgery.
Another chemokine reported to play a role in neutrophil 
migration is monocyte chemotactic protein (MCP) 1, a member 
of CC chemokine family. MCP-1 has also been referred to as 
CCL2. It is a ligand for CCR2 but can also bind the Duffy antigen 
receptor for chemokines (DARC) (50). CCL2 is one of the first 
and most highly expressed chemokines in response to fracture in 
both animal models (51–54) and human fractures (55) (Table 1). 
TAbLe 1 | Chemokines that are upregulated during acute phase of 
fracture healing.
Chemokine 
name
Specific 
chemokine 
receptors
Type of fracture (fracture 
model bone animal model)
Reference
CCL2 
[monocyte 
chemotactic 
protein  
(MCP) 1]
CCR2 Stress fracture (axial 
loading—ulna—rat)
Wu et al. (51)
Rundle et al. 
(52)
Xing et al. (54)
Ishikawa et al. 
(53)
Hoff et al. (55)
Single fracture (3-point 
bending—tibia—mouse)
Not stabilized single fracture 
(3-point bending—tibia—mouse)
Single fracture (rib - mouse)
Single fracture (human)a
CCL3 
[macrophage 
inflammatory 
protein 1 alpha 
(MIP-1a)]
CCR1, 
CCR5
Single fracture (3-point 
bending—tibia—mouse) Single 
fracture (human)a
Rundle et al. 
(52), Hoff 
et al. (55)
CCL4 
[macrophage 
inflammatory 
protein 1 beta 
(MIP-1b)]
CCR1, 
CCR4, 
CCR5
Single fracture (femur-human)a Hoff et al. (55)
CCL5 
(Regulated 
upon Activation, 
Normally 
T-Expressed, 
and presumably 
Secreted)
CCR1, 
CCR3, 
CCR5
Single fracture (femur-human)a Hoff et al. (55)
CCL7 (MCP-3) CCR1, 
CCR2, 
CCR3
Not stabilized single fracture 
(3-point bending—tibia—
mouse). Single fracture 
(Femur–human)a
Xing et al. 
(54), Hoff 
et al. (55)
CCL8 (MCP-2) CCR1, 
CCR2, 
CCR5
Not stabilized single fracture 
(3-point bending—tibia—mouse)
Xing et al. (54)
CCL11 (Eotaxin) CCR3, 
CCR2, 
CCR5
Single fracture (femur—human)a Hoff et al. (55)
CXCL1, CXCL2, 
CXCL3
CXCR2 Segmental defect (5 mm bone 
defect—femur—rat)
Förster 
et al (49)
CXCL10 (IFN-
γ-inducible 
protein 10)
CXCR3 Single fracture (femur—human)a Hoff et al. (55)
CXCL8 
(interleukin-8)
CXCR1, 
CXCR2, 
IL8R
Single fracture (femur-human)a Hoff et al. (55)
CXCL12 
(stroma cell-
derived factor 1)
CXCR4, 
CXCR7
Segmental defect and live bone 
graft (mouse)
Kitaori et al. 
(90)
aFracture type not reported.
3
Edderkaoui Chemokines and Fracture Healing
Frontiers in Endocrinology | www.frontiersin.org March 2017 | Volume 8 | Article 39
CCL2 is involved in regulating neutrophil migration (56), angio-
genesis, and macrophage infiltration in several inflammatory 
processes (57, 58) as well as regulating the migration of CD4+ 
T regulatory cells (59). Furthermore, CCL2 has been shown to 
be expressed at the periosteum around the fracture site during 
fracture healing (53), suggesting that CCL2 is involved in both 
postfracture inflammation and bone remodeling.
It has been previously reported that tumor necrosis factor 
alpha (TNFα) enhances neutrophil recruitment in early postfrac-
ture inflammation and promotes the recruitment of monocytes 
by stimulating CCL2 production (7). Furthermore, depletion 
of neutrophils by Ly6G neutralizing antibody or inhibition of 
the CCL2 chemokine receptor CCR2 in a murine tibial fracture 
model resulted in significantly impaired fracture healing (7), 
while early treatment with TNFα increased neutrophil infiltra-
tion to the fracture area, as well as the expression of CCL2, when 
compared to untreated fractures (7). In another study with open 
tibial fracture, it has been reported that local treatment with low 
concentrations of TNFα enhanced fracture repair (60). This illus-
trates the importance of postfracture inflammation and especially 
the roles of TNFα and CCL2 in fracture healing. Moreover, the 
expression level of CCl2 was increased in patients with systemic 
skeletal disease such as osteoporotic patients (61), and the serum 
level of CCL2 was greater up to 4 weeks postsurgery in patients 
with type 2 diabetes compared to healthy patients (62). In both 
cases, patients suffered from fragility fractures, and the delay in 
fracture healing was obvious in type 2 diabetic patients, which 
suggested that increased level of CCL2 in the serum is one of the 
leading causes to impaired fracture healing in diabetic patients.
In an anabolic regimen, intermittent treatment with parathy-
roid hormone (PTH) caused MCP-1 expression to increase over 
time, eventually reaching 200-fold higher levels after 14 days of 
treatment. This in turn was accompanied by an increase in bone 
volume in the PTH-treated animals, compared to untreated 
control animals (63). Together, these data suggest that in addi-
tion to its role in chemotaxis of monocytes and neutrophils and 
osteolysis (64) during inflammatory bone remodeling, CCL2 
might also be involved in bone formation during skeletal repair. 
However, this remains to be tested.
Macrophage inflammatory protein 1 alpha, also known as 
CCL3, binds to CCR1 and CCR5 (Table 1), which are receptors 
that mediate CCL3 chemotactic functions. CCL3 is produced by 
macrophages, natural killer cells, fibroblasts, and mast cells. Its 
expression in fracture callus was found to be upregulated dur-
ing the first 3 days postfracture in both animal (52) and human 
models (55). In models with systemic inflammation, such as a 
rat diabetic model, increased levels of CCL3 in serum was also 
associated with delayed fracture healing, indicating the impor-
tance of a well-controlled inflammation on the overall process 
of fracture healing (65). In contrast to CCL2, the role of CCL3 in 
postfracture healing has not been well investigated.
Macrophage inflammatory protein 1 beta, also known as 
CCL4, binds the CCR1, CCR4, and CCR5 receptors (Table 1). 
CCL4 is secreted by major leukocytes such as T cells, B cells, and 
monocytes (66), and its expression was observed to be upregu-
lated in fracture hematoma within 3 days postfracture, in parallel 
with an increase in the number of monocytes (55). Chondrocytes, 
in particular hypertrophic chondrocytes, have been identified as 
another source of CCL4. Expression of CCL4 by these cells has 
been shown to be dependent on TNFα in diabetic fractures (67). 
This suggests a role for TNFα and CCL4 in the loss of cartilage 
that is observed during the process of diabetic fracture healing. 
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However, Lin et al. (68) have reported a differential expression 
of CCL4 in mesenchymal stem cells (MSCs) treated with high-
mobility group box. These data together illustrate a complex role 
of CCL4 in fracture healing that still needs to be investigated.
The chemokine regulated upon Activation, Normally 
T-Expressed, and presumably secreted, also called CCL5, binds 
CCR1, CCR3, and CCR5 (Table 1) and is expressed in T lym-
phocytes. CCL5 promotes the recruitment and activation of 
inflammatory cells such as monocytes (69), lymphocytes (70), 
mast cells (71), and eosinophils (72). In the case of infection 
by pathogens, it is known to play a protective effect, through its 
interaction with CCR5 and the downstream ERK1/ERK2 and 
AKT signaling pathways. In a study of human fractures, CCL5 
levels increased both at the site of the fracture hematoma and in 
the surrounding bone marrow (55). The magnitude of increase 
was greater in the fracture hematoma compared to surrounding 
bone marrow, an effect that can be likely explained by increased 
infiltration of T cells.
Monocyte chemotactic protein 3, also known as CCL7, binds 
the CCR1, CCR2, and CCR3 receptors. CCL7 is another mediator 
of pro-inflammatory pathways by virtue of its ability to activate 
leukocytes (73, 74). Previous studies have identified CCL7 as a 
homing factor for MSCs (75). In a mouse model, mRNA levels 
of CCL7 increased as early as 1 day postfracture (53), peaked at 
2 days postfracture (53, 54), with a subsequent decline beginning 
at 3 days postfracture, but combined trauma model resulted in 
a significant increase in the level of CCL7 in plasma as early as 
6 h postfracture that lasted up to 3 days postinjury compared to 
control non-injured animals (76).
Monocyte chemotactic protein 2, also known as CCL8, binds 
to the CCR1, CCR2, and CCR5 receptors. CCL8 attracts leuko-
cytes and possesses various immunomodulating functions. Like 
other CC family chemokines, it influences mononuclear cell types 
(77). CCL8 was found to be upregulated (Table 1) during the first 
7 days postfracture (54).
Eotaxin, also known as CCL11, binds the CCR2, CCR3, and 
CCR5 receptors, thus affecting the migration of eosinophils that 
express the CCR3 receptor, as well as monocytes that express 
both CCR2 and CCR5 (78). It has been reported that pretreat-
ment of human monocytes with eotaxin reduces the binding of 
CCL2, the selective ligand for the CCR2, to monocytes (78) as 
well as the binding of CCL5 and CCL4 to CCR5. In previous 
studies (78), pretreatment of human monocytes with eotaxin 
triggered CCR5 activity at low concentrations of the ligand, 
while CCR2 was not activated by doses as high as 1 μM eotaxin, 
which suggested that eotaxin is a CCR5 agonist and a CCR2 
antagonist (78). In fracture calluses, CCL11 was found to be 
upregulated within 3  days postfracture (Table  1) in human 
models (55).
IFN-γ-inducible protein 10 (IP10), also called CXCL10, 
binds to CXCR3 and is secreted from a variety of cells, includ-
ing monocytes, endothelial cells, and fibroblasts, in response to 
interferon (79). CXCL10 inhibits bone marrow colony formation 
(80). It is a chemoattractant for human monocytes and T cells 
and promotes T cell adhesion to endothelia (80). Its expression 
is upregulated by both interferons and other inflammatory 
stimuli. It was found to be upregulated in fracture surrounding 
bone marrow in humans (Table 1), in parallel with an increase 
in the level of IFN-γ and TNFα and an increase in the number of 
CD3+ and CD3+CD4+ T cells in the surrounding bone marrow 
(55). Serum level of CXCL10 was found to be elevated in fracture 
patients with type 2 diabetes mellitus compared to patients with 
diabetes without fracture and normal patient with fracture (81). 
However, what role IP10 plays during fracture healing remains 
to be determined.
Interleukin-8, or CXCL8, binds the CXCR1, CXCR2, and 
IL-8R receptors (82, 83). IL-8 induces migration of hematopoi-
etic progenitor cells through stimulation of the β2-integrin LFA-1 
pathway (84). IL-8 levels have also been shown to be upregulated 
to a greater degree in fracture hematoma than in the surround-
ing bone marrow (Table 1), in parallel with an increase in the 
number of monocytes, granulocytes, and CD34+ HSCs (55). This 
suggests a role for IL-8 in HSC infiltration in response to bone 
injury.
Stroma cell-derived factor 1, also called CXCL12, binds the 
CXCR4 and CXCR7 receptors on the cell surface of responsive 
cells (85, 86). Local expression of CXCL12 has been shown to 
attract hematopoietic and endothelial progenitors to ischemic 
sites (87, 88). It is also expressed in bone marrow stroma cells 
(89) and has been reported to be upregulated at the endosteal 
surface around the injured bone from 7 to 14 days postsurgery 
(89). However, in other studies, CXCL12 levels have been 
reported to peak at different time points postfracture. For exam-
ple, in a murine segmental bone graft model, CXCL12 levels were 
increased at the periosteum of the live bone graft from the first 
day of surgery, and its level continued increasing with time (90). 
In another murine model of fracture healing, CXCL12 expression 
was found in the fracture callus of hypertrophic cartilage and 
in immature cartilage near the pre-existing cortical bone (91). 
One explanation for the discrepancy in the time when CXCL12 
expression peaks after fracture may be due to the specific nature 
of the injury. In some injuries, oxygen tension may change rapidly 
and since CXCL12 is reportedly regulated by a hypoxia-specific 
transcription factor, hypoxia-inducible factor 1, the expression of 
CXCL12 may increase rapidly after the blood supply is stopped 
in those models (92).
CXCL12 is well accepted as a major chemokine that plays a 
critical role in fracture repair. It is involved in fracture repair 
through possibly two mechanisms. One is by recruiting endothe-
lial progenitor cells, thus contributing to increased angiogenesis 
(87), a key phase in fracture repair. The other involves enhancing 
the homing of osteoblastic progenitors to promote new bone 
formation (93).
In the presence of inflammation, endothelial cells are stimu-
lated to increase the surface expression of adhesion molecules, 
such as selectins, as well as integrin ligands such as vascular cell 
adhesion molecule-1 and intercellular adhesion molecule-1. 
Subsequently, chemokines produced at the site of injury bind and 
activate chemokine receptors that are present at high concentra-
tions on the surface of endothelial cells (94, 95). Once activated, 
chemokine receptors permit the transcytosis of chemokines from 
one side to other side of vascular endothelial membrane, result-
ing in chemotaxis. The level of chemokines and the time of their 
bioavailability around the injured bone and in blood circulation 
FiGURe 1 | Hypothetical model for the involvement of chemokines in 
fracture healing. Fracture induces secretion of TNFα and IL-6 as well as 
CXCLs that attract neutrophils. Neutrophils will induce monocyte chemotaxis 
through CXCL8 and CCL2 secretion. Then, since monocytes secrete several 
chemokines, such as CCL2, CCL4, and CCL7, that are known to attract 
MSC. These later will migrate toward fracture callus and secrete CXCL12 that 
will bind to CXCR4 and regulate osteogenesis and fracture healing.
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are key factors that influence cell recruitment to the injured bone 
for subsequent fracture repair.
FUNCTiONAL STUDieS USiNG 
KNOCKOUT MiCe
Animal models involving targeted knockout (KO) of selective 
chemokines and their receptors have been used to evaluate the 
role of chemokines in fracture repair process. Studies involving 
KO of DARC (52), CCL2/CCR2 (53), and CXCL12/CXCR4 (90) 
have illustrated a key role of chemokines in fracture healing. 
However, the role for a number of other chemokines such as 
CCL3 (96), CCL5 (97, 98), and CCL7 (75), found to be upregu-
lated during the early phase of fracture healing and function as 
chemoattractants for MSCs, remains to be elucidated.
Postfracture inflammation has been evaluated in our mouse 
model using standard closed femoral fracture at the mid-
shaft (52). The mRNA expression levels of IL-1β, IL-6, tumor 
necrosis factor, and CCL2, which binds to DARC and CCR2, 
were increased 1  day postfracture. However, the magnitude of 
increase was lower in DARC-KO fracture calluses, consistent 
with a reduced inflammatory response. Accordingly, the number 
of macrophages was significantly reduced around the fractures in 
DARC-KO mice compared to wild type mice. This was associated 
with greater collagen (COL) II expression at 3 days and COL-X 
at 7 days postfracture, compared to wild-type mice, suggesting 
that lack of DARC expression in DARC-KO mice led to an early 
or premature fracture cartilage formation and differentiation. 
However, by 21  days postfracture, histological analysis did not 
show any difference in fracture healing between DARC-KO and 
wild-type mice. This may have been the result of a reduction in 
the recruitment of osteoclast precursors to the fracture callus in 
DARC-KO mice, which in turn has increased the time required 
for the transition from cartilage callus to bone.
By using a rib fracture model and graft exchanges, Ishikawa 
et al. (53) have reported delayed fracture healing at 21 days post-
fracture in both CCL2-KO and CCR2-KO mice and that blockade 
of the CCR2 receptor only in the early phase of healing caused 
delayed fracture healing in wild-type mice. The discrepancy 
between our model and the CCL2-KO model could be due to 
CCL2 expression not being sufficiently reduced in DARC-KO 
mice so as to cause a delay in fracture healing (52). Furthermore, 
the finding that CCL2 exhibits a significant chemotactic effect on 
neutrophils (56) and MSCs (53) but has no effect on osteogenesis 
or chondrogenesis (53) suggests that the effect of CCL2 on frac-
ture healing occurs via early neutrophil recruitment and MSC 
recruitment to the fracture site for subsequent bone formation.
Other studies have also reported the importance of MSC 
recruitment in fracture healing (99). By using heterozygous 
CXCL12+/– and CXCR4+/– mice, Kitaori et al. (90) have dem-
onstrated that CXCL12 recruits MSCs to the injured bone post-
fracture for subsequent bone formation. Furthermore, it has been 
reported that following fracture, a CXCL12- and BMP2-positive 
perivascular cell population is recruited along the endosteum. 
This is then followed by an increase in BMP2 levels that leads 
to downregulation of CXCL12, a step that is essential for the 
differentiation of CXCL12 and BMP2+ cells during osteogenesis. 
Moreover, CXCL12 has been shown to regulate BMP-2-stimulated 
osteogenic differentiation (100), while the CXCR4 receptor is 
involved in regulating osteoblast development in postnatal bone 
(101). Therefore, we conclude that CXCL12 signaling may have 
roles in fracture healing that extend beyond cell recruitment, 
including direct effects on MSC proliferation and differentiation 
into cells of the chondrogenic and osteogenic lineages.
CONCLUSiON
In conclusion, various chemokines are involved in postfracture 
inflammation and healing, and their induction and involve-
ment in the whole process are dose, site, and time dependent. 
Two chemokines have been investigated extensively for their 
role in fracture healing: CCL2 and CXCL12. CCL2 is involved 
in neutrophil recruitment, which is an early stage of fracture 
healing and in MSC infiltration for subsequent fracture repair. 
The importance of CCL2 and its specific receptor CCR2 in the 
progress of fracture healing have been demonstrated in mouse 
models (KO mice) that lack CCL2 or CCR2 expression and which 
showed delayed healing. However, an increase in CCL2 levels 
in plasma postfracture has been associated with a likelihood of 
delayed fracture healing. CXCL12, which is expressed in bone 
marrow and perivascular stroma cells, is crucial for the recruit-
ment of MSC to the injured bone postfracture, a necessary step for 
subsequent bone formation. On the basis of the above findings, 
we proposed a model (Figure 1) where fracture induces secre-
tion of TNFα and Il-6, as well as CXCLs that attract neutrophils. 
Neutrophils would be expected to induce monocyte chemotaxis 
6Edderkaoui Chemokines and Fracture Healing
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via stimulation of CCL2 secretion. Then, once monocytes secrete 
several chemokines, such as CCL2, CCL4, and CCL7, known to 
attract MSC, these cells will be induced to migrate toward fracture 
callus and secrete CXCL12. CXCL12 will in turn bind to CXCR4 
and regulate BMP2 effects on osteogenesis and fracture healing. 
Currently, no published study has investigated the involvement of 
CCL4 and CCL7 in fracture healing. Thus, the issue of whether 
other chemokines are involved in fracture healing and how they 
interact with each other in the fracture healing process remains 
to be investigated. A comprehensive understanding of the role 
of chemokines in the fracture healing process could lead to 
development of chemokine-based therapies to promote healing 
of non-union fractures.
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